Clinical Trials Logo

Clinical Trial Summary

The 'Experimental Human Pneumococcal challenge' (EHPC) model is a way of putting drops of bacteria into the nose. Investigators have studied this model of putting bacteria in the nose safely in over 1500 volunteers over the past decade with no serious side effects and now want to test the model using a different strain of the bacteria that is commonly found in the community, SPN3. The aim of this study is to determine how much pneumococcus is needed to achieve nasal colonisation and how long the bacteria live in the nose for before natural immune responses eradicate them. By doing this, Investigators will then be able to test how well future vaccines prevent colonisation with pneumococcus. Investigators want to learn more about how the immune system responds to nasal colonisation with pneumococcus, again to help with development of new vaccines.


Clinical Trial Description

In this study, investigators propose to determine the optimal dose and isolate of SPN3 to establish colonisation in the human nasopharynx, as well as improving knowledge of immune responses to SPN3 colonisation. The results from this study will be used to inform development of improved SPN3 vaccines and to inform design of future pneumococcal vaccine RCTs. To increase the relevance of the EHPC model and its use for assessing future vaccines such as V114, investigators are proposing here to set up an EHPC model with carefully selected non-proprietary SPN3 strains. Investigators will conduct a safety and dose-ranging study to determine the optimum SPN3 strain and dose for colonisation acquisition and confirm the dose in a subsequent larger cohort in a reproducibility study and will study mucosal and systemic immune responses to this serotype and their association with protection against colonisation acquisition and clearance. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05535868
Study type Interventional
Source Liverpool School of Tropical Medicine
Contact Kelly L Davies, BSc
Phone +44 151 702 9391
Email kelly.davies@lstmed.ac.uk
Status Recruiting
Phase N/A
Start date August 1, 2022
Completion date August 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04594785 - Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection
Completed NCT00471757 - Etiology of Community Acquired Pneumonia
Recruiting NCT04974294 - PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2) Phase 4
Not yet recruiting NCT05140720 - Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age N/A
Recruiting NCT05429541 - Pneumococcal Carriage and Serotype Distribution in Children With Otitis Media in Malaysia.
Completed NCT00808821 - Pharyngeal Carriage Rates and Genetic Typing of Group A Streptococcus and Streptococcus Pneumonia Among Israeli Military Basic Trainees N/A